164 related articles for article (PubMed ID: 11281398)
21. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature.
Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR
Pediatrics; 1999 Apr; 103(4):e44. PubMed ID: 10103336
[TBL] [Abstract][Full Text] [Related]
22. Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease.
Chung LW; Yeh SP; Hsieh CY; Liao YM; Huang HH; Lin CY; Chiu CF
Ann Hematol; 2008 May; 87(5):421-3. PubMed ID: 18040684
[No Abstract] [Full Text] [Related]
23. Thalidomide as therapy for intestinal chronic GVHD.
Lopez J; Ulibarrena C; Garcia-Laraña J; Odriozola J; Pérez de Oteyza J; Sastre JL; Navarro JL
Bone Marrow Transplant; 1993 Mar; 11(3):251-2. PubMed ID: 8467293
[No Abstract] [Full Text] [Related]
24. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
[No Abstract] [Full Text] [Related]
25. Chronic Ulcer by Cutaneous GvHD After Bone Marrow Transplantation Treated With Skin Allograft From HLA-Identical Donor: Case Report and Literature Review.
Amendola F; Gazzola R; Lombardo M; Caminiti R; Dagna L; Baruffaldi-Preis FW
Int J Low Extrem Wounds; 2016 Jun; 15(2):139-41. PubMed ID: 27009789
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic skin grafting for extensive skin chronic graft-versus-host disease.
Kondo S; Tamura K; Makino S; Takamatsu Y
Int J Hematol; 1994 Aug; 60(2):151-5. PubMed ID: 7948965
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation.
McCarthy DM; Kanfer EJ; Barrett AJ
Biomed Pharmacother; 1989; 43(9):693-7. PubMed ID: 2696566
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide for treatment of graft-versus-host disease.
Vogelsang GB; Hess AD; Santos GW
Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
[TBL] [Abstract][Full Text] [Related]
29. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
30. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
31. Graft-vs-host disease.
Tran K; Kaplan J; Kamino H; Latkowski JA
Dermatol Online J; 2013 Dec; 19(12):20710. PubMed ID: 24365001
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
[TBL] [Abstract][Full Text] [Related]
33. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow transplantation for chronic lymphocytic leukemia.
Bandini G; Michallet M; Rosti G; Tura S
Bone Marrow Transplant; 1991 Apr; 7(4):251-3. PubMed ID: 2070129
[TBL] [Abstract][Full Text] [Related]
35. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus.
Eckardt A; Starke O; Stadler M; Reuter C; Hertenstein B
Oral Oncol; 2004 Sep; 40(8):811-4. PubMed ID: 15288836
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide-induced perioral neuropathy.
Elad S; Galili D; Garfunkel AA; Or R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1997 Oct; 84(4):362-4. PubMed ID: 9347498
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
40. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
Margolis J; Vogelsang G
Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
